Medpace Holdings earnings beat by $0.40, revenue topped estimates
Medpace Holdings (MEDP) reported Q3 EPS of $4.84, beating estimates by $0.40, with revenue of $716M, slightly above expectations. The company provided FY 2026 guidance, with EPS and revenue estimates close to consensus. The stock is up 20.90% over the past year and has seen 8 positive EPS revisions in the last 90 days, according to Investing.com.
How this was made
The 30-second read
Why it matters
The key tradable inputs are the EPS and revenue beats plus the FY 2026 EPS and revenue ranges, which can shift forward estimates and valuation multiples.
Market read
A company-specific earnings and guidance update that can drive near-term repricing of forward earnings expectations.
What to watch
The article does not break out segment growth, client concentration, or margin drivers, which can dominate post-earnings follow-through even when EPS beats.
Background
Medpace Holdings is a clinical research services provider; this article summarizes its Q3 results and FY 2026 guidance versus analyst consensus.
Ticker impact
Medpace reported Q3 EPS of $4.84, beating the $4.44 estimate, and revenue of $716M versus $714.47M, plus FY 2026 EPS and revenue guidance.
Likely upward bias as the market prices in stronger-than-expected earnings power and modestly higher FY 2026 outlook.
The article provides both the earnings beat and explicit FY 2026 EPS and revenue ranges versus consensus, which are direct inputs to valuation and expectations.
Market effects
Reinforces demand and pricing resilience signals for clinical research services, though the article is single-name and not a sector-wide datapoint.
Limited, as it is a US-listed single-company earnings print without broader macro linkage.
Low, no international regulatory or cross-border deal details beyond the company’s own results.
Counterpoint
The revenue beat is marginal versus consensus, so the stock reaction may hinge more on the quality of guidance and margins than on the headline EPS outperformance.
Key entities
- companyMedpace Holdings
Reported Q3 EPS and revenue versus consensus and issued FY 2026 EPS and revenue guidance ranges.
